Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Acrux ( (AU:ACR) ) just unveiled an update.
Acrux Ltd announced a change in the director’s interest, with Tim Oldham acquiring 2,866,719 unlisted rights, as approved at the company’s AGM on November 25, 2025. This change reflects a strategic move to align the director’s interests with the company’s long-term goals, potentially impacting stakeholder confidence and Acrux’s market positioning.
The most recent analyst rating on (AU:ACR) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Acrux stock, see the AU:ACR Stock Forecast page.
More about Acrux
Acrux Ltd operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drug delivery solutions. The company primarily offers products that enhance the delivery of medications through the skin, catering to various therapeutic areas and aiming to improve patient outcomes.
Average Trading Volume: 318,326
Technical Sentiment Signal: Sell
Current Market Cap: A$5.75M
For an in-depth examination of ACR stock, go to TipRanks’ Overview page.